A study led by researchers at Open Targets, EMBL's European Bioinformatics Institute (EMBL-EBI), the University of Cambridge and others has identified a set of plasma proteins that could be used to diagnose and monitor patients with metabolic dysfunction-associated steatotic liver disease (MASLD). It was published today in Nature Metabolism.
Source: Medical Xpress
